ArticleJournal of cancer research and clinical oncology2011

A monoclonal antibody targeted against epidermal growth factor receptor variant III enhances cisplatin efficiency.

Na Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.